Tolkach Y, Kristiansen G (2018) The heterogeneity of prostate cancer: A practical approach. Pathobiology 85:108–116. https://doi.org/10.1159/000477852
Article CAS PubMed Google Scholar
Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, Marzo AMD, Nelson PS, Yegnasubramanian S (2021) Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol 18:79–92. https://doi.org/10.1038/s41585-020-00400-w
Sathianathen NJ, Konety BR, Crook J, Saad F, Lawrentschuk N (2018) Landmarks in prostate cancer. Nat Rev Urol 15:627–642. https://doi.org/10.1038/s41585-018-0060-7
Huang CC, Deng FM, Kong MX, Ren Q, Melamed J, Zhou M (2014) Re-evaluating the concept of ‘dominant/index tumor nodule’ in multifocal prostate cancer. Virchows Arch 464:589–594. https://doi.org/10.1007/s00428-014-1557-y
Article CAS PubMed Google Scholar
Ibeawuchi C, Schmidt H, Voss R, Titze U, Abbas M, Neumann J, Eltze E, Hoogland AM, Jenster G, Brandt B, Semjonow A (2013) Genome-wide investigation of multifocal and unifocal prostate cancer-are they genetically different? Int J Mol Sci 14:11816–11829. https://doi.org/10.3390/ijms140611816
Article CAS PubMed PubMed Central Google Scholar
Karavitakis M, Ahmed HU, Abel PD, Hazell S, Winkler MH (2011) Tumor focality in prostate cancer: Implications for focal therapy. Nat Rev Clin Oncol 8:48–55. https://doi.org/10.1038/nrclinonc.2010.190
Stamatiou KN, Dilernia GC, Ilias GK, Daskalopoulos GK, Koutelekos IK, Marianou SN, Sofras FA (2009) The phenomenon of multifocality does not affect the biologic behavior of histologic prostate carcinoma. Med Sci Monit 15:61–63
Choi YH, Yu JW, Jeong BC, Seo SI, Jeon SS, Lee HM, Jeon HG (2019) Histological characteristics of the largest and secondary tumors in radical prostatectomy specimens and implications for focal therapy. Diagn Pathol 14:1–6. https://doi.org/10.1186/s13000-019-0782-8
Zhang W, Wang T, Wang Y, Zhu F, Shi H, Zhang J, Wang Z, Qu M, Zhang H, Wang T, Qian Y, Yang J, Gao X, Li J (2022) Intratumor heterogeneity and clonal evolution revealed in castration-resistant prostate cancer by longitudinal genomic analysis. Transl Oncol 16:101311. https://doi.org/10.1016/j.tranon.2021.101311
Article CAS PubMed Google Scholar
Xu J, Isaacs WB, Mamawala M et al (2021) Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients. Prostate 81:703–709. https://doi.org/10.1002/pros.24140
Article CAS PubMed PubMed Central Google Scholar
Wu B, Lu X, Shen H, Yuan X, Wang X, Yin N, Sun L, Shen P, Hu C, Jian H, Wang D (2020) Intratumoral heterogeneity and genetic characteristics of prostate cancer. Int J Cancer 146:3369–3378. https://doi.org/10.1002/ijc.32961
Article CAS PubMed Google Scholar
De Vargas RL, Jacobs A, Rueschoff JH et al (2022) Single-cell proteomics defines the cellular heterogeneity of localized prostate cancer. Cell Reports Med 3:100604. https://doi.org/10.1016/j.xcrm.2022.100604
Løvf M, Zhao S, Axcrona U et al (2019) Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity. Eur Urol 75:498–505. https://doi.org/10.1016/j.eururo.2018.08.009
Article CAS PubMed Google Scholar
Boutros PC, Fraser M, Harding NJ et al (2015) Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet 47:736–745. https://doi.org/10.1038/ng.3315
Article CAS PubMed Google Scholar
Salami SS, Hovelson DH, Kaplan JB et al (2018) Transcriptomic heterogeneity in multifocal prostate cancer. JCI insight 3:e123468. https://doi.org/10.1172/jci.insight.123468
Article PubMed PubMed Central Google Scholar
Andreoiu M, Cheng L (2010) Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol 41:781–793. https://doi.org/10.1016/j.humpath.2010.02.011
Vendramin R, Litchfield K, Swanton C (2021) Cancer evolution: Darwin and beyond. EMBO J 40:e108389. https://doi.org/10.15252/embj.2021108389
Article CAS PubMed PubMed Central Google Scholar
Erickson A, Hayes A, Rajakumar T, Verrill C, Bryant RJ, Hamdy FC, Wedge DC, Woodcock DJ, Mills IG, Lamb AD (2021) A Systematic Review of Prostate Cancer Heterogeneity: Understanding the Clonal Ancestry of Multifocal Disease. Eur Urol Oncol 4:358–369. https://doi.org/10.1016/j.euo.2021.02.008
Abeshouse A, Ahn J, Akbani R et al (2015) The Molecular Taxonomy of Primary Prostate Cancer. Cell 163:1011–1025. https://doi.org/10.1016/j.cell.2015.10.025
Wang X, Grasso CS, Jordahl KM et al (2020) Copy number alterations are associated with metastatic-lethal progression in prostate cancer. Prostate Cancer Prostatic Dis 23:494–506. https://doi.org/10.1038/s41391-020-0212-8
Article CAS PubMed PubMed Central Google Scholar
Hernández-Llodrà S, Juanpere N, de Muga S et al (2017) ERG overexpression plus SLC45A3 (prostein) and PTEN expression loss : Strong association of the triple hit phenotype with an aggressive pathway of prostate cancer progression. Oncotarget 8:74106–74118. https://doi.org/10.18632/oncotarget.18266
Article PubMed PubMed Central Google Scholar
Segalés L, Juanpere N, Lorenzo M, Albero-González R, Fumadó L, Cecchini L, Bellmunt J, Lloreta-Trull J, Hernández-Llodrà S (2019) Strong cytoplasmic ETV1 expression has a negative impact on prostate cancer outcome. Virchows Arch 475:457–466. https://doi.org/10.1007/s00428-019-02573-1
Article CAS PubMed Google Scholar
Hernández-Llodrà S, Segalés L, Juanpere N, Lorenzo M, Salido M, Nonell L, López D, Rodríguez-Vida A, Bellmunt J, Fumadó L, Cecchini L (2021) Lloreta-Trull J (2021) SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence. Prostate 81:1267–1277. https://doi.org/10.1002/pros.24218
Article CAS PubMed Google Scholar
Hernández S, Font-Tello A, Juanpere N, de Muga S, Lorenzo M, Salido M, Fumadó L, Serrano L, Cecchini L, Serrano S, Lloreta J (2016) Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset. Prostate 76:854–865. https://doi.org/10.1002/pros.23176
Article CAS PubMed Google Scholar
Salgado R, Aftimos P, Sotiriou C, Desmedt C (2015) Evolving paradigms in multifocal breast cancer. Semin Cancer Biol 31:111–118. https://doi.org/10.1016/j.semcancer.2014.07.002
Simmer F, van der Linden RLA, Ligtenberg MJL et al (2021) Multifocal Colorectal Cancer—Do Intraluminal Metastases Occur? Gastroenterology 160:1853–1855. https://doi.org/10.1053/j.gastro.2020.12.010
Leventakos K, Peikert T, Midthun DE et al (2017) Management of Multifocal Lung Cancer: Results of a Survey. J Thorac Oncol 12:1398–1402. https://doi.org/10.1016/j.jtho.2017.05.013
Article PubMed PubMed Central Google Scholar
Karavitakis M, Ahmed HU, Abel PD, Hazell S, Winkler MH (2012) Anatomically versus biologically unifocal prostate cancer: A pathological evaluation in the context of focal therapy. Ther Adv Urol 4:155–160. https://doi.org/10.1177/1756287212447092
Article PubMed PubMed Central Google Scholar
Tourinho-Barbosa R, Srougi V, Nunes-Silva I, Baghdadi M, Rembeyo G, Eiffel SS, Barret E, Rozet F, Galiano M, Cathelineau X, Sanchez-Salas R (2018) Biochemical recurrence after radical prostatectomy : what does it mean? Int Braz J urol 44:14–21. https://doi.org/10.1590/S1677-5538.IBJU.2016.0656
Article PubMed PubMed Central Google Scholar
Kneppers J, Krijgsman O, Melis M, de Jong J, Peeper DS, Bekers E, van der Poel HG, Zwart W, Bergman AM (2019) Frequent clonal relations between metastases and non-index prostate cancer lesions. JCI Insight 4:e124756. https://doi.org/10.1172/jci.insight.124756
Article PubMed PubMed Central Google Scholar
Rice KR, Furusato B, Chen Y, McLeod DG, Sesterhenn IA, Brassell SA (2009) Clinicopathological Behavior of Single Focus Prostate Adenocarcinoma. J Urol 182:2689–2694. https://doi.org/10.1016/j.juro.2009.08.055
Masterson TA, Cheng L, Mehan RM, Koch MO (2011) Tumor focality does not predict biochemical recurrence after radical prostatectomy in men with clinically localized prostate cancer. J Urol 186:506–510. https://doi.org/10.1016/j.juro.2011.03.106
Iremashvili V, Pelaez L, Manoharan M, Acosta K, Rosenberg DL, Soloway MS (2012) Tumor focality is not associated with biochemical outcome after radical prostatectomy. Prostate 72:762–768. https://doi.org/10.1002/pros.21481
Arora K, Barbieri C (2018) Molecular Subtypes of Prostate Cancer. Curr Oncol Rep 20:55–58. https://doi.org/10.1007/s11912-018-0707-9
Comments (0)